Hechen Bioworks completes over RMB 100 million Series A financing to accelerate biomanufacturing R&D and industrialization

Recently, Hechen Bioworks completed a Series A financing round of over RMB 100 million. Investors include Anhui Venture Capital, Changxing Fund, Guoyuan Equity, Insight Capital, and industry player Shike New Materials, with X&Q Capital acting as financial advisor. This round of financing will be primarily directed toward the construction of the company's large-scale production base, as well as the introduction of AI technology to empower and enhance the company's synthetic biology and precision chemistry technology platform, accelerating the research, development, and industrialization process of biomanufacturing.

Founded in 2022, Hechen Bioworks has a core founding team with deep expertise, coming from renowned academic institutions and industry leaders such as Unilever, DuPont, Jilin University, and Tianjin University of Science and Technology. The team possesses a global strategic vision, multidisciplinary R&D backgrounds, and extensive experience in integrated industrialization. Its core members have an average of nearly two decades of deep industry experience, covering key links across the entire industrial chain, including strain engineering, fermentation, extraction and purification, chemical synthesis, formulation R&D, and market channels.

Since its establishment, Hechen Bioworks has consistently leveraged "synthetic biology plus precision chemistry" as its core technology foundation — using biomanufacturing to address pain points such as high pollution, high energy consumption, and hazardous operations associated with traditional chemical processes, while employing chemical synthesis to solve challenges in precise material polymerization and performance improvement. The company focuses on innovative raw material R&D and diversified application scenarios, steadily building its full-chain biomanufacturing technological capabilities. It has formed two key business segments: specialty material solutions and nutrition and health solutions.

In 2025, Hechen Bioworks successfully completed pilot-scale validation at production level for its core products, including biobased material monomers and small amino acids. At the same time, the company launched the world's first freeze-dried functional skincare preparation microsphere, achieving full-chain closed-loop validation from self-developed core raw materials to final product realization. Currently, Hechen Bioworks is accelerating the construction of its thousand-ton-level production base. In the future, the company will fully enter a new phase of large-scale, standardized production, continuously releasing its capacity advantages.

Based on Hechen Bioworks' leading "synthetic biology plus precision chemistry" technology platform, its core product pipeline not only possesses a high degree of industrialization certainty and leading technological competitiveness, but also enjoys broad market prospects, laying a solid foundation for the company's sustained growth.

Using renewable biomass as raw materials, Hechen Bioworks produces chemicals such as bio-based polyamines and polyols through efficient and green processes. These products offer high purity, sustainability, customizability, and cost controllability, aligning with the global carbon neutrality and carbon peaking strategy as well as the trend toward green manufacturing. The company has broken the technological stranglehold of overseas companies on key material monomers. Currently, its products have completed pilot-scale validation and passed application trials with multiple downstream customers, accelerating the transition toward large-scale production. The high-refractive-index optical material monomer project has already achieved mass production, with products having passed testing by multiple optical material customers and entered commercial application. Meanwhile, customer validation work has also been initiated in new application areas such as optical adhesives, optical devices, augmented reality equipment, and energy storage batteries.

Hechen Bioworks focuses on high-value-added small amino acids. Leveraging its self-built synthetic biology chassis and fermentation and extraction technology platform, it has achieved technological breakthroughs in its products. Currently, several products have completed pilot-scale validation at production level and can be widely used in areas such as pharmaceutical intermediates, functional foods, cosmetic ingredients, and animal nutrition, providing downstream customers with efficient and cost-effective alternative solutions.

Shifting from selling active raw materials to providing solutions, the company's core positioning has moved from pure molecular synthesis to functional design. Leveraging its self-developed active ingredient delivery technology, Hechen Bioworks efficiently and stably encapsulates active ingredients and achieves precise targeted release, effectively addressing industry pain points such as the easy deactivation of active ingredients, temperature sensitivity, and low utilization rates, while significantly improving their bioavailability and efficacy. The company offers a full-chain solution covering "active ingredients, formulation, process, and service," enhancing product premium and customer loyalty. Currently, this full-chain solution has already achieved commercial realization in the efficacy skincare sector. At the same time, Hechen Bioworks is using its delivery technology as a core platform to horizontally expand into areas such as feed additives, functional health products, and regenerative medicine, continuously exploring the value of its technological applications and enriching its product matrix.

This round of financing will be primarily directed toward the construction of an annual thousand-ton-scale production base. The base will adopt full-process intelligent control and modular flexible production design, serving as a core pillar for Hechen Bioworks to break through development bottlenecks and seize market opportunities. On one hand, the company will overcome capacity constraints, significantly increasing the supply capacity of core products such as specialty material monomers and small amino acids to meet potential downstream market demand. On the other hand, it will further validate and optimize the maximum conversion efficiency of metabolically engineered strains in large-scale industrial settings, continuously exploring production process potential, reducing production costs, and strengthening the market competitiveness of Hechen Bioworks' products.

At the same time, Hechen Bioworks will focus on introducing AI technology. By deeply integrating AI into and enhancing its core "synthetic biology plus precision chemistry" technology platform, the company aims to improve the development efficiency and iteration speed of target products, reinforce its technological leadership, and promote the deep integration of its technology platforms. This will accelerate Hechen Bioworks' transition from "technological leadership" to "market leadership."